Tonix Pharmaceuticals Presents Preclinical Immuno-Oncology Data at AACR 2026, Highlighting Potential in Gastric Cancer and Immunotherapy
Tonix Pharmaceuticals announced new preclinical data for TNX-1700 and TNX-4700 at AACR 2026, showing potential in gastric cancer and as a BTLA-targeting immunotherapy, which could expand its oncology pipeline.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented new preclinical data from its immuno-oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, highlighting the potential of two drug candidates, TNX-1700 and TNX-4700. The data, shared through one oral and two poster sessions, underscore the company's efforts to expand beyond its central nervous system (CNS) focus into oncology.
TNX-1700, a modified enzyme targeting the tumor microenvironment, demonstrated potential in reducing inflammation and tumor progression in gastric cancer models. The preclinical findings also showed favorable pharmacokinetics, suggesting the drug could be effectively delivered to tumors. Gastric cancer remains a challenging disease with limited treatment options, making TNX-1700 a promising candidate for further development.
TNX-4700, a monoclonal antibody targeting BTLA (B- and T-lymphocyte attenuator), showed promising in vitro activity. BTLA is an immune checkpoint receptor that can inhibit T-cell responses in tumors. The data indicated that TNX-4700 could be effective either as a standalone therapy or in combination with other checkpoint inhibitors, such as PD-1 or CTLA-4 blockers. This positions TNX-4700 as a potential new tool in the growing field of cancer immunotherapy.
The presentation at AACR, a premier cancer research conference, provides Tonix with visibility among oncology researchers and potential partners. The company is primarily known for its CNS portfolio, including the recently approved fibromyalgia drug TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), which marked the first new treatment for fibromyalgia in over 15 years. Tonix also markets acute migraine products Zembrace® SymTouch® and Tosymra®.
Beyond oncology, Tonix continues to advance its CNS pipeline. The company is evaluating TONMYA in Phase 2 trials for major depressive disorder and acute stress disorder. Additionally, TNX-2900 is Phase 2 ready for Prader-Willi syndrome, a rare genetic disorder. In immunology, Tonix is developing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection.
The new immuno-oncology data could diversify Tonix's revenue streams and address significant unmet medical needs. However, all product development candidates are investigational, and their efficacy and safety have not been established. The full press release is available at https://ibn.fm/Oly6o.
For more information on Tonix Pharmaceuticals, visit the company's newsroom at https://ibn.fm/TNXP.